TICKERNERD
Menu
ODDODDConsumer Defensive · Household & Personal Products

ODD Stock Forecast: ODDITY Tech Ltd. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$19
−0.11% on the day

The 11 Wall Street analysts covering ODDITY Tech Ltd. hold a median 12-month price target of $17 — -8.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 2 Oct 2026 — in the weakest quartile.

Market cap
$872.7M
Ticker Nerd rank
14 / 100
Median analyst target
$17
Analysts covering
11
Revenue$180.5M−25.1% y/y
Operating income−$1.3M
Net income$12.9M
Free cash flow$17.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.4%
1M
+30.4%
YTD
−53.0%
1Y
−68.8%
From 52W high
−68.8%
From 52W low
+92.7%
$10
$61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ODD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ODDITY Tech Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Oct 2026
14 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
91
Size
46
Value
30
Quality
26
Accruals
26
Issuance
19
Volatility
9
Momentum
9
Growth
8

Revisions (91): Analysts have, on balance, been raising their forecasts.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ODD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ODD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26ODDHigh $21Median $17Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
0 Buy8 Hold3 Sell
Low $9Median $17High $21

The green dot is the last close — the median target sits −8.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
21 Sept 2026JP MorganReinstatesNeutral$18
10 Sept 2026Evercore ISI GroupMaintainsIn-Line—
10 Sept 2026Evercore ISI GroupMaintainsIn-Line$15 → $21
10 Sept 2026Morgan StanleyMaintainsEqual-Weight$10 → $17
10 Sept 2026Morgan StanleyMaintainsEqual-Weight—
10 Sept 2026Truist SecuritiesMaintainsHold—
10 Sept 2026Truist SecuritiesMaintainsHold$16 → $18
9 Sept 2026JefferiesMaintainsHold$16 → $18
9 Sept 2026JefferiesMaintainsHold—
8 Sept 2026NeedhamReiteratesHold—
8 Sept 2026NeedhamReiteratesHold—
1 Sept 2026Truist SecuritiesMaintainsHold—
1 Sept 2026Truist SecuritiesMaintainsHold$12 → $16
4 June 2026Evercore ISI GroupMaintainsIn-Line—
4 June 2026Evercore ISI GroupMaintainsIn-Line$23 → $15
3 June 2026BarclaysMaintainsUnderweight—
3 June 2026BarclaysMaintainsUnderweight$13 → $8.00
3 June 2026Goldman SachsDowngradeSell—
3 June 2026Goldman SachsDowngradeSell$16 → $8.00
3 June 2026KeybancDowngradeSector Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ODD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ODD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, ODDITY Tech Ltd. returned −68.8% against +16.2% for the S&P 500, dividends included.

ODD vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26ODDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ODD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+616.3%
Analysts raising
1
Analysts cutting
0
Fundamentals

ODDITY Tech Ltd. (ODD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
86.0×

Cheaper than 8% of US stocks

Price / sales
1.3×

Cheaper than 63% of US stocks

Price / book
3.7×

Cheaper than 26% of US stocks

EV / EBITDA
246.7×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
−25.1%

Higher than 10% of US stocks

Earnings growth (YoY)
−73.8%

Higher than 6% of US stocks

Gross margin
68.7%

Higher than 82% of US stocks

Operating margin
−0.7%

Higher than 31% of US stocks

Net margin
2.2%

Higher than 53% of US stocks

Returns & dividend
Return on equity
5.1%

Higher than 54% of US stocks

Return on assets
−0.5%

Higher than 42% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ODDITY Tech Ltd. (ODD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ODDITY Tech Ltd. has a market value of $872.7M and an enterprise value of $1.3B.

  • Revenue in the twelve months to 30 June 2026: $679.1M. The latest quarter shrank 25.1% year on year.

  • Net income over the same four quarters: $15.2M, a 2.2% net margin.

  • Diluted earnings per share, trailing twelve months: $0.24.

  • Free cash flow in the twelve months to 30 June 2026: −$35.5M.

  • ODDITY Tech Ltd. spent $162.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 46.1M.

  • Trailing P/E: 86.0×; forward P/E: 16.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • ODDITY Tech Ltd. employs 658 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 2 Oct 2026

Data provided by Twelve Data

Peers

ODD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHousehold & Personal Products
CompanyMarket capTKN rank
ODDODDITY Tech Ltd.$872.7M
14
HELEHelen of Troy Ltd.$621.9M
76
EPCEdgewell Personal Care Co.$1.3B
78
HNSTThe Honest Co., Inc.$580.4M
86
MAGNMagnera Corp.$415.5M
47
SPBSpectrum Brands Holdings, Inc.$1.8B
99
NWLNewell Brands, Inc.$2.3B
68

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ODDITY Tech Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ODD news & analysis

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition

GlobeNewsWire · 28 Sept 2026positive

Nanjing Leads Biolabs announced that its proprietary PD-L1/4-1BB bispecific antibody, opamtistomig (LBL-024), has been granted Orphan Drug Designation by Japan's MHLW for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This marks the third such designation for the drug, following earlier ones from the U.S. FDA and the European Commission, expanding its global regulatory recognition into an Asian market.

Why it matters — A watcher of ODD would care because this third orphan drug designation for opamtistomig extends its regulatory recognition into a strategically important Asian market, broadening the drug's global footprint across Japan, the U.S., and Europe.

Earnings Estimates Moving Higher for Oddity Tech (ODD): Time to Buy?

Zacks Investment Research · 15 Sept 2026positive

Zacks reports that Oddity Tech (ODD) shares have begun gaining and may continue rising in the near term, based on solid upward earnings estimate revisions for the company.

Why it matters — A watcher of ODD would care because improving earnings estimate revisions signal growing analyst confidence in the company's near-term performance.

Oddity Tech: Turnaround Potential And Discounted Debt Value Lever

Seeking Alpha · 11 Sept 2026positive

The article discusses Oddity Tech's turnaround potential, citing improving acquisition costs, growing revenue from SpoiledChild, and longer-term opportunities from METHODIQ and Labs. It also highlights the company's convertible bonds trading at a discount with a 0% coupon, which it calls cheap debt offering flexibility and a value lever.

Why it matters — ODD watchers would care because the piece highlights multiple growth avenues and a discounted convertible debt position that could provide financial flexibility beyond IL MAKIAGE's recovery.

Why Oddity Tech's Stock Skyrocketed 26.5% Today

The Motley Fool · 9 Sept 2026positive

Oddity Tech's stock rose 26.5% after reporting second-quarter sales of $181 million, down 25% year over year but slightly ahead of Wall Street's target. Earnings per share fell from $0.92 to $0.20, yet topped analyst estimates by a penny.

Why it matters — A stock surge of 26.5% alongside results that beat both revenue and earnings forecasts signals investor approval of Oddity Tech's quarterly performance despite declining sales.

Oddity Tech Ltd. (ODD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 9 Sept 2026neutral

Seeking Alpha published the full transcript of Oddity Tech Ltd.'s (ODD) Q2 2026 earnings call. The item presents the company's quarterly earnings discussion as conducted by its management.

Why it matters — A transcript of the Q2 2026 earnings call gives ODD watchers direct access to the company's latest financial results and management commentary.

FAQ

Frequently asked questions about ODD stock

What is the ODD stock price forecast for 2026-2027?

The 11 Wall Street analysts covering ODDITY Tech Ltd. have a median 12-month price target of $17, with estimates ranging from $9 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ODD stock a buy right now?

Of the 11 analysts covering ODDITY Tech Ltd., 0 rate it a Buy, 8 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks ODDITY Tech Ltd. 14 out of 100 across roughly 4,600 US stocks as at 2 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ODD?

As at 2 Oct 2026, ODDITY Tech Ltd. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (91 of 100).

Will ODD stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies -8.7% from the last close, and Ticker Nerd's factor model ranks ODDITY Tech Ltd. 14 out of 100 as at 2 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ODD stock forecast for 2030?

No analyst covering ODDITY Tech Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ODD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $21 over the next 12 months.

How has ODD stock performed over the past year?

ODDITY Tech Ltd. returned -68.8% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ODDITY Tech Ltd. do?

Oddity Tech Ltd. Class A Ordinary Shares represent ownership in Oddity Tech Ltd., a consumer technology company focused on beauty and wellness.

What is the latest news on ODD?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition". Nanjing Leads Biolabs announced that its proprietary PD-L1/4-1BB bispecific antibody, opamtistomig (LBL-024), has been granted Orphan Drug Designation by Japan's MHLW for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This marks the third such designation for the drug, following earlier ones from the U.S. FDA and the European Commission, expanding its global regulatory recognition into an Asian market.

Company

About ODDITY Tech Ltd.

Oddity Tech Ltd. Class A Ordinary Shares represent ownership in Oddity Tech Ltd., a consumer technology company focused on beauty and wellness. The company develops and operates digital-first brands through an online platform that uses data science, machine learning, and computer vision to identify consumer needs and create product offerings. Its current business centers on cosmetics, personal care, and wellness products distributed directly to consumers, with brands that serve a broad international customer base. Oddity Tech also supports its consumer business with technology-driven product development and digital commerce capabilities, making the company notable for blending software-like tools with consumer packaged goods. Oddity Tech Ltd. is headquartered in Tel Aviv-Jaffa, Israel, and its Class A Ordinary Shares are the public equity class used to represent investor ownership in the business.

CEO Mr. Oran Holtzman · 658 employees · Israel · https://oddity.com